Acompanhe as Notícias da Recifes

In a new research report, scientists at Johns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center say they have found a potential therapeutic target that can boost the potency of a chemotherapy drug used to treat certain cancers. The study is published in

Cancer cells are quick to develop resistance to anti-tumor drugs. New research by scientists from the University of California, Davis, shows how cancers adapt to evade a class of anti-tumor drugs called BET inhibitors and offers hope for more effective therapies.

Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some and turning deadly disease into a manageable chronic condition in others. But these drugs work for only a subset of patients, with few indications why—a k

Researchers at the Mount Sinai Tisch Cancer Center have identified a previously underrecognized folate deficiency that may cause severe anemia in some patients receiving PARP inhibitors, a widely used class of targeted cancer therapies. Their findings, published in the latest iss

Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi), according to a study published online June 23 in Rheumatology.

Media stories, social media posts and the U.S. Centers for Disease Control and Prevention have asserted that selective serotonin reuptake inhibitors (SSRIs)—a class of medication commonly used to treat mental health conditions including depression and anxiety—may increase people'

A target trial emulation found that people with type 2 diabetes who started glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy had a slightly higher risk of ischemic optic neuropathy (ION), a rare condition involving reduced blood flow to the optic nerve that can cause su